Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis
Gwénaël Le Teuff, Nathalie Cozic, Jean-Christophe Boyer, Valérie Boige, Robert B. Diasio, Julien Taı̈eb, Didier Meulendijks, Claire Palles, Matthias Schwab, Maarten J. Deenen, Carlo R. Largiadèr, Anthony M. Marinaki, Barbara Jennings, Yvonne Wettergren, Antonello Di Paolo, Eva Groß, Barna Budai, Stephen P. Ackland, André B. P. Kuilenburg, Howard L. McLeod, G. Milano, Fabienne Thomas, Marie‐Anne Loriot, David Kerr, Jan H.M. Schellens, Pierre Laurent‐Puig, Qian Shi, Jean‐Pierre Pignon, Marie-Christine Étienne-Grimaldi, FUSAFE collaborative group
Topics & Concepts
DPYDDihydropyrimidine dehydrogenaseMedicineToxicityInternal medicineClinical endpointConcomitantCapecitabineOncologyPharmacogeneticsConfidence intervalGastroenterologyClinical trialCancerGenotypeFluorouracilThymidylate synthaseBiologyGeneticsColorectal cancerGeneColorectal Cancer Treatments and StudiesBiochemical and Molecular ResearchBlood disorders and treatments